About
LUNAC Therapeutics is a University of Leeds spin-out developing first-in-class oral and intravenous small-molecule inhibitors of activated Factor XII (FXIIa) to prevent pathological thrombosis without increasing bleeding risk.
Explore LUNAC Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.